Eventide Asset Management Q3 2023 significant ownership

Eventide Asset Management is required to file a 13D/G report to the SEC when the ownership of a company's total stock issue exceeds 5%.

Eventide Asset Management Q3 2023 significant holdings filed using form 13D/G when ownership exceeds 5% of a company's total stock issue.
FiledShares Percentage
Cogent Biosciences, Inc.February 14, 20232,589,7783.7%
ESSA Pharma Inc.Sold outFebruary 14, 202300.0%
Freeline Therapeutics Holdings plcFebruary 14, 20235,920,7659.1%
KnowBe4, Inc.Sold outFebruary 14, 202300.0%
Praxis Precision Medicines, Inc.February 14, 20233,518,0627.5%
Prometheus Biosciences, Inc.February 14, 20231,032,9382.2%
SUTRO BIOPHARMA, INC.Sold outFebruary 14, 202300.0%
Vital Farms, Inc.Sold outFebruary 14, 202300.0%
Zymeworks Inc.Sold outFebruary 14, 202300.0%
Entasis Therapeutics Holdings Inc.February 14, 2022590,6021.2%
Kala Pharmaceuticals, Inc.Sold outFebruary 14, 202200.0%
KalVista Pharmaceuticals, Inc.February 14, 2022138,8210.6%
PLIANT THERAPEUTICS, INC.February 14, 202242,4990.1%
Vital Farms, Inc.February 14, 20222,950,0007.3%
ARYA SCIENCES ACQUISITION CORP.Sold outFebruary 12, 202100.0%
CHIASMA, INCFebruary 12, 20213,000,3265.2%
Magenta Therapeutics, Inc.February 12, 20211,000,0002.1%
STEMLINE THERAPEUTICS INCSold outFebruary 12, 202100.0%
ZOGENIX, INC.Sold outFebruary 12, 202100.0%
SUNESIS PHARMACEUTICALS INCSold outFebruary 04, 202000.0%
Tracon Pharmaceuticals, Inc.Sold outFebruary 13, 201900.0%
VERACYTE, INC.February 13, 2019930,0002.3%
VICAL INCSold outFebruary 13, 201900.0%
ESSA Pharma Inc.March 09, 201827,719,41019.9%
8point3 Energy Partners LPFebruary 12, 20181,461,4005.2%
Zosano Pharma CorpFebruary 13, 2017272,0001.6%

Compare quarters

Export Eventide Asset Management's holdings